Thrombolex has announced that results of its First-In-Human (FIH) trial confirm the early safety and feasibility of using the Bashir Endovascular Catheter for pharmacomechanical catheter-directed thrombolysis (CDT), in patients with acute pulmonary embolism (PE).
The data, presented at the annual meeting of the American Venous Forum (AVF 2020; 3–6 March, Amelia Island, USA) by Riyaz Bashir (Temple University, Philadelphia, USA), showed a significant reduction in RV/LV and clot burden.
“The results from the First-in-Human study for the Bashir Endovascular Catheter are exciting. PE patients treated were real-world patients that had high thrombus burden and major right ventricular dilation, and the amount of thrombus removed with less than 14mg of tissue plasminogen activator (r-tPA) was impressive. I look forward to seeing what this device can do in a larger study and a randomised cohort,” said Akhilesh Sista (NYU Langone Health, New York, USA), co-principal investigator of the Thrombolex FIH study.
Please click the link below to read the entire article.
First-in-human results for Bashir Endovascular Catheter meet safety and feasibility endpoints
